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Introduction
Chronic heart failure (HF) is a rising global epidemic with an increasing incidence [1, 2] . It is estimated that more than 35 million people suffer from this disease worldwide [1, 2] . Heart transplantation (HTX) remains the reference standard therapy for patients who progress to end-stage HF. However, because of a scarcity of donor organs, HTX is only possible in a very limited number of patients.
Though initially introduced as bridge-to-recovery (BTR) and bridge-to-transplantation (BTT) for patients at high risk of mortality on the HTX waiting list [3] , left ventricular assist devices (LVADs) have evolved to become a common therapy for end-stage HF patients [4] . Even for patients ineligible for HTX because of contraindications, LVADs are now used as a last resort in the form of destination therapy (DT) [5] . In the USA the rate of patient enrollment has continued at a pace exceeding 2500 implants per year [6] . The survival of LVAD patients has improved greatly over time and is reported to be 80% and 70% at 1 and 2 years after implantation by the largest LVAD registry, the Interagency Registry for Mechanically Assisted Circulatory Support (INTER-MACS) [4] .
Despite its great benefit, the use of an LVAD is associated with a high risk of complications [4, 7] . Bleeding is the most frequently observed complication, occurring in over a third of the patients [4, 8] . Besides the risk of bleeding, these patients are also at risk of thromboembolic events and pump thrombosis, which is associated with high mortality [4, 9] . Although the design of the third-generation LVAD has improved greatly, these hemostatic complications remain high [4, 7] . The introduction of an LVAD into the circulatory system results in an altered hematological balance as a consequence of blood-pump interactions, changes in hemodynamics, the rheology, and the concomitant need for anticoagulation therapy throughout the whole period on LVAD support. The majority, if not all, LVAD patients experience a form of platelet dysfunction and impaired von Willebrand factor activity, leading to acquired coagulopathy disorders [10, 11] .
The present review focuses on acquired coagulopathies, describing the incidence, impact and underlying mechanism of acquired coagulopathy disorders in patients supported by LVADs. In addition, we will discuss diagnostic and management strategies for these acquired coagulopathies.
The evolution of LVADs
The first successful use of a cardiopulmonary bypass system dates back to 1953, when Dr Gibbon successfully corrected a patient's atrial septal defect while on a cardiopulmonary bypass system [12] . A decade later, the first use of a pneumatically driven ventricular assist device system was reported by Dr Debakey and his colleagues [13] . Although this device was revolutionary, it was limited to short-term support [13] . The Novacor (World Heart Corp., Oakland, CA, USA) left ventricular assist device was the first implantable LVAD that was used as BTT [14] . Since then a number of devices have been introduced, both paracorporeal and fully implantable. However, the course of advanced heart failure treatment drastically changed with the introduction of the HeartMate XVE (Thoratec Corporation, Pleasanton, CA, USA), and its approval by the Food and Drug Administration for destination therapy in 2003 [3] . With this pneumatically driven pulsatile-flow pump, LVAD therapy was now also a treatment option for patients ineligible for HTX. Although it was the most successful device up till then, it was associated with reduced durability and a high risk of bleeding, infections and thromboembolic events [15] . The HeartMate XVE was therefore soon followed by second and third-generation devices, which were smaller, more durable, and able to provide continuous blood flow.
The HeartMate II (Abbott Laboratories, Chicago, IL, USA), a continuous-flow LVAD with an axial rotor and mechanical contact bearings, is currently the most utilized device worldwide [4, 16] , followed by the HeartWare HVAD (HeartWare Inc., Framingham, MA, USA), also a continuous-flow LVAD that has a suspended rotor through a passive magnetic and hydrodynamic bearing that eliminates friction, heat and component wear [4, 16] . The successor of the HeartMate II is the HeartMate 3 (Abbott Laboratories), a continuous-flow LVAD with a centrifugal pump containing a fully magnetically levitated rotor [17] . A new additional feature of the HeartMate 3 is the intrinsic pulse wave designed to avert stasis within the pump [18] . The HeartMate 3 has received the Conformit e Europ eenne mark (CE-mark) approval in Europe for short-term and long-term support, and is currently being studied in the USA for long-term support (ClinicalTrials.gov Identifier: NCT02224755). The successor of the HeartWare HVAD is the Miniaturized Ventricular Assist Device (MVAD), a smaller pump with a wide-bladed rotor design and magnetically suspended impeller. However, this device is still being investigated and is not yet not approved for clinical use in Europe and the USA (ClinicalTrials.gov Identifier: NCT01831544). A list of devices that are currently used is presented in Table 1 .
Hematological complications
Although the introduction of new devices and improved patient management has resulted in a decline in the complication rate over time, complications related to the hemocompatibility of the devices remain a significant problem [4] . The most common classifications used for these complications are described by the INTERMACS registry and include bleeding, neurologic events, hemolysis, pump thrombosis and venous or non-stroke-related arterial thromboembolic events [19] . The high risk of complications is one of the reasons why LVAD therapy has not yet been expanded to patients with less severe heart failure symptoms. Reducing these complications and improving management after the occurrence of a complication could support making LVAD therapy a suitable treatment option for these patients.
Bleeding is the most common complication after LVAD implantation, with an incidence ranging between 20% and 60%, depending on the definition used [4, 8, 20] . In addition, it is associated with high morbidity and mortality [21, 22] . The INTERMACS defines a bleeding episode as a suspected internal or external bleeding that results in death, re-operation, hospitalization or transfusion of red blood cells (≥ 4U red blood cells [RBC] within any 24-h period during the first 7 days, or any transfusion of RBC after 7 days following implantation). Patients are at high risk of major bleeding events in the postoperative period. Approximately 20% to 30% of the patients require a surgical re-exploration early after LVAD implantation due to bleeding episodes [23, 24] . Late bleeding events include non-surgical bleedings, mainly gastrointestinal (GI) bleeding or epistaxis [25, 26] . The mean time to first GI bleeding episode is reported to be 88 days (95% CI, 45-131) [27] . Over time a significant increase in the event rate of GI bleedings in patients supported with a CF-LVAD compared with pulsatile devices has been reported [27] [28] [29] . In addition, patients who experience a GI bleeding are also at higher risk of thromboembolic events [30] . Subsequently, this all leads to a higher burden for the patient and the healthcare system. The most frequent neurologic events observed in LVAD patients are ischemic strokes and intracranial hemorrhages. Although they are less frequently observed compared with bleeding events, the outcome after a neurologic event can be devastating. In a recent systematic review the overall neurologic event rate in 1110 LVAD patients was 9.8%, with 0.08 events per patientyear (EPPY) [9] . When comparing devices, ischemic stroke and intracranial hemorrhage occurred on average more in patients supported with a HeartWare device than in patients supported with a HeartMate II device (17% and 15% vs. 9% and 2%, respectively) [31, 32] . The leading cause of death since the introduction of the CF-LVADs has been neurologic events, with up to 20% of the patients having a neurologic event as a primary cause of death [4, 5, 33] . Furthermore, higher mortality rates have been reported after intracranial hemorrhagic events than ischemic strokes (median mortality rate 71% vs. 31%, respectively) [9] . Neurologic events severely impair the quality of life and can inhibit the patient's ability to operate the LVAD or to life independently.
Pump thrombosis and neurologic events are the most feared complications after LVAD implantation. Pump thrombosis is categorized as suspected or confirmed pump thrombosis and results in major device malfunctioning requiring device replacement or urgent transplantation if not treated quickly. The hazard for pump thrombosis is reported to peak early at 1 to 2 months and returns back to a low hazard after LVAD implantation, and thereafter gradually increases over time. A low pump thrombosis rate (4%) was reported during the initial experience with CF-LVADs [5]. Subsequently, it was suggested that a more liberal anticoagulation regimen might be beneficial in order to reduce the bleeding events [34, 35] . However, following the implementation of this less aggressive anticoagulation regimen a higher rate of pump thrombosis was observed and confirmed by the INTERMACS registry [36, 37] . This resulted in the reintroduction of a more intense anticoagulation therapy.
An overview of factors contributing to the risk of bleeding or thrombosis is presented in Fig. 1 . Because patients are at risk of both thromboembolic events and bleeding, a coagulopathy paradigm arises with the LVAD functioning as a double-edged sword.
Acquired coagulopathies
There are various underlying mechanisms that contribute to the risk of the above-mentioned hematological complications, including device hemocompatibility, use of antithrombotic therapy, GI angiodysplasias and acquired coagulopathies, such as von Willebrand disease (VWD) or platelet dysfunction [10, 11, 25, 38, 39] .
von Willebrand factor and von Willebrand disease
Although inherited VWD is a well-known cause of bleeding, acquired VWD, also known as acquired von Willebrand syndrome (AVWS), has attracted over the past couple of years the most attention with regard to a possible factor that explains the high rate of bleeding complications after LVAD implantation. von Willebrand factor (VWF) is a multimeric large glycoprotein with four types of domains that serve as binding sites for factor (F) VIII, the glycoprotein (GP) Iba and IIb/IIIa on platelets, the subendothelial matrix, and domains that interact with integrins or that mediate VWF multimerization [40] [41] [42] . The hemostatic potential of the VWF is associated with the size of the multimers, with a smaller size having less activity [43] . At sites of vascular injury, endothelium cells release a vast amount of large VWF multimers. VWF in turn mediates platelet adhesion and aggregation to the subendothelial matrix in order to achieve hemostasis or/ and formation of a platelet plug [42] . VWF especially promotes platelet aggregation in high shear stress circumstances. In addition, VWF is the carrier protein for FVIII, thereby protecting FVIII from rapid proteolytic degradation [42, 44] . A disintegrin and metalloprotease with thrombospondin type 1 repeat 13 (ADAMTS-13) cleaves the large VWF multimer when anchored to the subendothelial matrix [45] . Once cleaved, VWF is released into the circulation, where it is further reduced in size by ADAMTS-13 or through exposure to shear stress [45] .
VWD is the most common inherited bleeding disorder, with an incidence that ranges between 0.6% and 1.2% in the general population [46] . VWD is subdivided into types 1, 2 and 3. The most prevalent is type 1 (70-80% of the cases), and is characterized by a quantitative deficiency of VWF. Type 2 (20% of the cases) is caused by a dysfunctional VWF molecule and further categorized into type 2A, B, M and N depending on intrinsic characteristics of the VWF as a consequence of mutations in certain domains or alterations in the shape of the VWF [47] , resulting in an impaired VWF function. Finally, type 3 VWD (< 5% of the cases) is characterized by the absence of VWF and is the most severe form of VWD [47] . The severity of VWD varies based on the level of residual VWF activity, which does not solely depend on the level of VWF but also on the size of the multimers. Common bleeding complications observed in patients with VWD are epistaxis, gastrointestinal (GI) bleedings, postoperative bleeding, menorrhagia and hematomas [48] . In addition, GI bleedings from angiodysplasia, which is prevalent in type 2A, type 2B and type 3 VWD, are frequently observed in elderly VWD patients [49] . These complications are due to a lower level of VWF activity and especially seen in those individuals with a loss of large multimers, resulting in insufficient hemostasis [50] . Besides inherited VWD, different conditions and mechanisms have been described to result in an AVWS [51] .
Acquired von Willebrand syndrome
AVWS has been observed in patients with a variety of conditions such as autoimmune disorders, lymphoproliferative disorders and cardiovascular conditions, including LVAD patients [39, [52] [53] [54] [55] [56] . However, nearly all LVAD patients suffer from AVWS [39, 53, 55] . In an identical way to other cardiac conditions such as aortic stenosis (Heyde's syndrome), paravalvular leakage or hypertrophic cardiomyopathy, patients on LVAD support have a comparable loss in VWF activity [52, 53, 57, 58] . It is thought that this loss in activity is due to an increased shear stress as a consequence of the continuous-flow pump design and cardiac conditions [57] [58] [59] . Laboratory findings show a loss of large multimers, despite an increase in VWF antigen level (Ag), reduced binding of VWF to collagen (measured by VWF:CB activity) and ristocetin cofactor activity (VWF:RCo), similar to VWD type 2A [39, 55] . The ratio RCo:Ag is reduced (< 0.6) due to proteolysis of VWF. This loss in VWF activity is observed early in the postoperative period after LVAD implantation, persistent during LVAD support, and resolves after LVAD explantation or heart transplantation [55, 60] . Different mechanisms have been proposed to explain the development of AVWS in LVAD patients. Of these, shear stress and ADAMTS-13 have been studied the most. The presence of an LVAD in the blood circulation leads to significant changes, including increased level of shear stress and lower pulse pressure. As a consequence of increased shear stress the VWF disentangles and exposes the domains A1 and A2, which in turn promotes proteolytic cleavage by ADAMTS-13 and multimeric binding to platelets GP 1ba (Fig. 2) [61, 62] . In addition, binding of VWF multimers to platelets leads also to an increased proteolytic cleavage by ADAMTS-13 [63] . This subsequently results in VWF degradation into smaller multimers and reduced VWF:CB and VWF:RCo activity. This loss in function has been reported to be present in nearly all CF-LVAD types [53, 55, 56] .
Although nearly all CF-LVAD patients suffer from AVWS, not all patients experience bleeding events. This suggests that other pathways or factors, either protective or not, are also essential in determining the risk of bleeding or thrombosis in these patients. Some studies suggest that VWF multimers also modulate angiogenesis, as VWF is considered an inhibitor of angiogenesis [64, 65] . A loss of VWF multimers in patients with certain types of VWD or AVWS promotes angiodysplasia and arteriovenous malformations (AVM), which are accompanied by a high risk of GI bleeding [65] . Microcirculatory changes due to loss of or more weak pulsatility, and high capillary pressures in LVAD patients, have also been suggested to play a concomitant role.
Lower VWF activity could stimulate VEGF-dependent vascular proliferation, initiating angiogenesis, AVMs, and subsequently, lead to GI bleedings. The finding of a higher incidence of GI bleedings in older patients with type 2 VWD is also relevant for LVAD patients. Because an increasing number of older patients have implants as DT therapy, the burden of bleedings is only anticipated to increase.
Furthermore, other factors such as FXIII, serine protease granzyme, plasmin, free hemoglobin, calcium and thrombospondin-1 have been suggested to play a role in regulating VWF activity and hemostasis. Further studies have yet to determine their impact on VWF in LVAD patients. 
Platelet dysfunction
Platelets have an essential role in primary hemostasis. This process is initiated through the interaction of platelets with VWF (via the GP Ib-IX-V platelet receptor), and through adhesion of platelets to the extracellular matrix (via GP Ia/IIa or VI platelet receptor) at sites of vascular injury. Subsequently, platelets are activated, resulting in binding with fibrinogen, cross-linking with other platelets, and forming a platelet plug [66] . Platelet activation pathways include a variety of platelet secretion products (such as ADP and thromboxane A2), and local (coagulation) factors (such as collagen, thrombin and tissue factor), leading to up-regulation and activation of glycoprotein receptors on platelets and fibrin formation. Following activation, platelet aggregation, platelet-leukocyte binding and thrombus growth are stimulated by releasing a-and dense granules containing, among others, CXC chemokine ligand 4 (platelet factor 4, PF4), P-selectin, integrins and thrombospondin [66] .
Thrombocytopenia is frequently observed in the setting of cardiopulmonary bypass or cardiac surgery due to depletion of platelets. This drop in platelet counts occurs within 72 h and improves thereafter. Upon LVAD implantation, platelets are activated through increased shear stress, hemolysis and contact with foreign bodies [67, 68] . Activated platelets subsequently bind to VWF or fibrinogen on the surface of the pump that is exposed to blood. This is followed by platelet aggregation and, as described above, due to platelet secretion products and local (coagulation) factors a platelet plug is formed, which could grow extensively and occlude the device [67] . In addition, certain other conditions may predispose the patient to a hypercoagulable state, such as increased stress during systemic inflammatory responses, sepsis or preceding episodes of infections [69, 70] .
Besides AVWS, platelet dysfunction has been suggested to increase the risk of bleeding events. [10] Because primary hemostasis is initiated by VWF tethering platelets via glycoprotein membrane receptors, a dysfunction in either VWF or platelets could increase the risk of bleeding. Through increased shear stress, shedding of GPIba receptor can occur [71] . Platelet GPIba shedding has been reported to pre-exist in CF-LVAD patients and to increase post-implantation in patients who experience a bleeding event, in contrast to patients who did not bleed, in whom a constant decrease in platelet GPIba shedding was found [72] .
Furthermore, a high rate of platelet damage and dysfunction has been observed in patients supported with an LVAD [72] [73] [74] . Steinlechner et al., and more recently Baghei et al., reported that platelet aggregation is significantly reduced in the majority of patients after LVAD implantation [10, 74] . However, based on their data causality could not be established as platelet dysfunction was also present prior to LVAD implantation.
Finally, in a recent publication, Mondal et al. investigated a potential mechanism of platelet apoptosis in CF-LVAD patients who developed bleedings within 1 month post-implantation [73] . Higher platelet reactive oxygen (ROS) generation, a decrease in total antioxidant capacity and elevated oxidized low-density lipoproteins were observed in the bleeding group, suggesting that the body' antioxidant capacity may not have been sufficient to combat the deleterious effects of ROS in patients who experienced a bleeding event [73] . In addition, a reduction in BCl-2 and BCl-xL (pro-survival) protein expression was evident in LVAD patients, whereas the translocation of Bax into the platelet mitochondria and subsequent release of cytochrome C, which leads to downstream apoptotic events, was more prevalent in the bleeding group [73] . This suggests that there are intrinsic and extrinsic pathways leading to platelet apoptosis, which may play a key role in developing acquired platelet dysfunction.
The use of anticoagulation, AVWS and platelet dysfunction all contribute to and increase the cumulative risk of bleeding in LVAD patients. The above-mentioned pathways enable new domains for medical management strategies, which are desperately needed to prevent and reduce bleeding complications.
Heparin-induced thrombocytopenia
Heparin-induced thrombocytopenia (HIT) is a clinically significant syndrome, which is mediated by antibodies to the heparin-platelet factor 4 complex [75] . These antibodies can activate platelets and cause thrombocytopenia and thrombosis [75] . An interesting observation is that although bleeding is rare, GI bleeding is the most common type of bleeding in patients experiencing HIT [76] . Treatment includes cessation of all heparin exposure and initiation of an alternative anticoagulant.
Patients receiving LVADs often require prolonged heparin anticoagulation therapy in the perioperative period or during adverse events. In addition to systemic heparinization, the use of cardiopulmonary bypass seems to make LVAD patients more prone to HIT. The literature regarding HIT in LVAD patients is mainly limited to case reports. The incidence of HIT in LVAD patients has been reported to range between 4 and 26% [77, 78] . In addition, patients experiencing HIT did not have a decrease in survival or an increased risk of thromboembolism [77] . However, these studies are limited by the use of different types of older-generation devices.
Experience and data regarding other rare (inherited) coagulation disorders and use of LVADs are scarce and limited to case reports and case series [79] . Several case series on patients with an LVAD and hematologic conditions have been reported, including antiphospholipid syndrome, elevated FVIII activity, FV Leiden mutation, immune-mediated thrombocytopenia, lupus anticoagulant and protein C deficiency [79, 80] . Although these case series suggest that there is an impaired survival in patients with these coagulation disorders [79, 80] , no definitive conclusion can be reached due to the large variety in the underlying cause of these disorders and the small number of patients. Further research is needed to determine clinical outcomes, complication rates and optimal medical treatment options for these patients when receiving an LVAD.
Diagnosis and management
A difference in hemocompatibility has been demonstrated between rotary pumps (HeartMate II) and centrifugal pumps (HeartWare HVAD and HeartMate 2) [81, 82] . These key differences between devices mandate tailored and up-to-date diagnostic and management protocols. In addition, more emphasis on screening and assessment for inherited or acquired coagulation disorders prior to LVAD implantation could prevent unforeseen thrombotic and bleeding complications in the perioperative period. A comprehensive discussion of anticoagulation and management of complications is not covered here owing to other recent comprehensive reviews [83, 84] . In summary, because of the fear of pump thrombosis and the high risk of thromboembolic events, all LVAD patients receive anticoagulation and antiplatelet therapy. After the suggestion that a more liberal anticoagulation protocol might be permissible, an increase in the pump thrombosis rate was observed, and again a more intense anticoagulation protocol was introduced as the standard of care. The guidelines include vitamin K antagonist with an INR goal of 2.0-3.5 (Table 1 ) and aspirin (81-325 mg) depending on the type of device (Table 2 ) [85] . In a recent study by Nassif et al. the most optimal INR based on weighted mortality of thrombosis and bleeding was 2.6. Of note, a high aspirin hypo-responsiveness rate and failure of aspirin to adequately inhibit platelet function after LVAD implantation have been reported in a small cohort study (n = 26) [86] . Although no significant associations between aspirin hypo-responsiveness and thromboembolic events were reported, this suggests that high platelet reactivity is present early after LVAD implantation and that standard measurement of platelet activity might not be sufficient to determine its activity.
Because of the intrinsic hematological changes after LVAD implantation and the high risk of bleeding, diagnosis of AVWS should be considered prior to the onset of bleeding events. Diagnostic laboratory tests used to assess AVWS are the same as those used to assess inherited VWD and include the assessment of VWF antigen (VWF:Ag), the ability of VWF to bind to collagen (VWF:CB), its ability to agglutinate platelets (VWF: RCo), and the ratio of VWF:RCo/VWF:Ag [51] . VWF antigen quantifies the level of VWF in the plasma; however, a high plasma level does not always indicate a high level of activity. Therefore, the ratio of activity to antigen indicates the structural or functional abnormalities of the VWF, and is often decreased in LVAD patients. In addition, VWF multimer patterns can be determined by electrophoresis and densitometry in order to quantify a loss or decrease of large multimers [51] . Furthermore, FVIII activity (FVIII:C) should be measured. The VWF propeptide level is a marker of VWF biosynthesis. In case of an increase in VWF propeptide or a decrease in VWF:Ag level, the VWF propeptide:VWF:Ag ratio will be elevated, indicating an accelerated VWF clearance from the plasma [87] . With regard to ADAMTS-13 activity, additional research is required in order to determine its role in LVAD patients. Current data do not suggest that measurement of ADAMTS-13 levels will be helpful [88] .
An interesting yet under-appreciated topic is the measurement of platelet VWF (VWF stored in platelets). Although the importance of the contribution of platelet VWF to collagen adhesion has been demonstrated in a flow system and although it has been suggested that type 1 VWD patients' response to DDAVP is better if platelet VWF is normal, the literature regarding the value of platelet VWF in LVAD patients is scarce [89] .
Finally, as a result of anticoagulant treatment with vitamin k antagonists or heparin, the prothrombin time, INR and activated partial thromboplastin time may be abnormal. However, point-of-care tests such as thromboelastometry (ROTEM Tem International, Munich, Germany) or thomboelastography (TEG) devices, may provide us with more insight with regard to the viscoelasticity of the blood and the level of platelet aggregation. Although ROTEM and TEG are frequently used during cardiac surgery, studies regarding its use in LVAD patients are scarce and current use in protocols and risk prediction models following LVAD implantation is limited. Different devices with specific features are capable of detecting platelet dysfunction and VWF deficiency, including the PFA-200 (Siemens AG, Erlangen, Germany) and Multiplate (Roche Diagnostics International, Rotkreuz, Switzerland) [90] . The technical differences and detection principles are described elsewhere [90] . Succinctly, through a high shear force dynamic flow system, impedance aggregometry or viscoelastic blood property measurement, a differentiation can be made between types of platelet dysfunction, platelet activation sensitivity and platelet aggregation. However, prospective studies are warranted to determine the role of point-of-care devices in mechanical circulatory support patients.
Traditional treatment options for bleeding in AWVS include desmopressin, VWF-containing concentrates, recombinant (r) FVIIa, antifibrinolytics, intravenous immunoglobin and/or plasmapheresis [51] . The use of desmopressin has been anecdotally described for treatment of GI bleeding in LVAD patients. Furthermore, rFVIIa has also been used to control life-threatening bleeding in LVAD patients and resulted in a reduction of blood loss and transfusion requirement [91, 92] . Although the use of rFVIIa has been remarkably safe for hemophiliacs with inhibitors, its use in LVAD patients is accompanied with a potential risk of thrombosis [91, 92] . Most patients are treated using FVIII/VWF concentrates. The long-term use of these concentrates will result in accumulation of FVIII and high FVIII levels, which theoretically may also increase the risk of thrombosis [47] . However, the use of FVIII/VWF concentrate is limited by the rapid degradation of VWF in LVAD patients [93, 94] . Preventing this rapid degradation through inhibition of VWF proteolysis by ADAMTS-13 may represent a novel treatment option. An ex-vivo study using donor whole blood exposed to LVAD-like supraphysiological shear stress showed that inhibition of ADAMTS-13 by doxycycline decreased VWF degradation and improved VWF function without hyper-activation of platelets [95] . In a similar manner, Rauch et al. have identified an antibody (mAb508) that was able to block the VWF-ADAMTS-13 interactions, resulting in an inhibition of 83 AE 8% when used at a maximum dose [96] . Although very promising, before its effectiveness is assessed in LVAD patients, additional research is required in order to determine both the safety and feasibility of these possible treatment options, taking into account the high risk of thrombotic events. GI bleeding is the most frequently observed bleeding event in AVWS patients, often as a consequence of arteriovenous malformation or Dieulafoy lesions [47, 65] . This is also seen in LVAD patients [27] . Besides a temporary cessation of anticoagulation during a GI bleeding episode, endoscopy and treatment of a suspected lesion are recommended in LVAD patients [27] . It has been described that preventing recurrence of GI bleeding was best obtained by prophylactic VWF concentrate in VWD patients [49] . However, targeted treatment strategies at the time of a GI bleed are needed. This can include desmopressin administered intravenously (0.3 lg per kilogram of body weight), intranasally (total dose, 300 lg [150 lg per nostril]; in patients with body weight < 50 kg, only one dose of 150 lg) or subcutaneously (0.3 lg per kilogram). Another option is the use of intravenously administered VWF/FVIII concentrate, or solely VWF concentrate. The aim should be to normalize the VWF:RCo activity and FVIII activity until the GI bleeding has resolved. However, close monitoring of FVIII and VWF levels is warranted, as different VWF concentrates have different ratios of FVIII to VWF, leading to different levels of VWF activity and FVIII levels in the circulation. High FVIII levels may theoretically predispose LVAD patients to thrombotic complications. In addition, the fibrinolysis inhibitor tranexamic acid could be added to the treatment (orally 1 g, three or four times daily) as it reduces mucocutaneous (re-)bleedings. Other medical treatment options for GI bleedings that have gained attention more recently include atorvastatin, thalidomide and octreotide [97] [98] [99] . Through an anti-angiogenic pathway, thalidomide and atorvastatin reduce the rate of bleeding from AVMs and the need for transfusion in VWD patients [97, 99] . Notwithstanding the observed anti-angiogenic effect of these drugs, these observations and the use of VWF (/ FVIII) concentrates need confirmation in LVAD patients through larger prospective randomized trials. These drugs have not been registered for use in LVAD patients or patients with AVWS.
Finally, a reduced pump speed does not seem to decrease VWF degradation, although this has only been quantified in a small in vivo study [100] . In addition, the finding that patients receiving third-generation devices that function at a lower RPM also experience a loss in VWF activity and GI bleeding rate similar to that seen with second-generation devices, suggests that lower pump speed does not add to the preservation of VWF [39, 56] . Ultimately, only after device explantation or transplantation will the AVWS resolve.
Conclusion
In conclusion, in the last decade LVADs have evolved greatly and we eagerly await further developments. The increasing incidence of heart failure and subsequent increasing use of LVADS demand tailored treatment and management strategies. Acquired coagulopathies are highly prevalent, with nearly all, if not all, patients experiencing AVWS. However, a definite association with bleeding events has yet to be determined. A variety of specialized techniques and assays can be used to diagnose patients with coagulopathies, although their clinical implications and consequences have to be determined in larger cohorts. In the case of acquired von Willebrand syndrome diagnosed using specific VWF assays in a bleeding LVAD patient, desmopressin or VWF/FVIII concentrates can be administered. Other promising therapies are emerging, but still require validation in LVAD patients. These complex coagulation disorders in LVAD patients require a multidisciplinary approach. Future studies focusing on these diagnostic and management therapies and assessing their safety should be a priority for cardiologists, thoracic surgeons and hematologists. Addendum R. Muslem and F. W. G. Leebeek wrote the paper and K. Caliskan critically reviewed the paper. All authors approved the final manuscript.
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